• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Jazz Pharmaceuticals plc

    6/2/25 5:03:17 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JAZZ alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001193210
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Jazz Pharmaceuticals plc
    SEC File Number
    001-33500
    Address of Issuer
    FIFTH FLOOR, WATERLOO EXCHANGE
    WATERLOO ROAD
    DUBLIN
    IRELAND
    4
    Phone
    353-1-634-7800
    Name of Person for Whose Account the Securities are To Be Sold
    COZADD BRUCE C
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    common
    Merrill Lynch
    3075B Hansen Way
    1st Floor
    Palo Alto � CA � 94304
    1000108950.006163284106/02/2025
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    common03/05/2020Equity CompensationJazz Pharmaceuticals PLCCheckbox not checked100003/05/2020Equity Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Bruce C Cozadd
    FIFTH FLOOR, WATERLOO Exchange
    WATERLOO ROAD
    Dublin � L2 � 4
    common05/02/202550060000.00
    Bruce C Cozadd
    FIFTH FLOOR, WATERLOO Exchange,
    WATERLOO ROAD
    Dublin � L2 � 4
    Common05/01/20251000116350.00
    Bruce C Cozadd
    FIFTH FLOOR, WATERLOO EXCHANGE
    WATERLOO ROAD
    Dublin � L2 � 4
    common04/01/20251500185625.00
    Bruce C Cozadd
    FIFTH FLOOR, WATERLOO EXCHANGE
    WATERLOO ROAD
    Dublin � L2 � 4
    common03/03/20256500937625.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/02/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    06/05/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Bruce C Cozadd

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $JAZZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JAZZ

    DatePrice TargetRatingAnalyst
    3/7/2025$145.00 → $179.00Neutral → Buy
    UBS
    2/26/2025Overweight → Neutral
    Cantor Fitzgerald
    2/13/2025$130.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    12/12/2024$140.00 → $175.00Equal-Weight → Overweight
    Morgan Stanley
    6/5/2024$169.00Buy
    Goldman
    1/3/2024$160.00Outperform
    Robert W. Baird
    11/27/2023$170.00 → $135.00Buy → Neutral
    UBS
    9/29/2023Mkt Perform
    Raymond James
    More analyst ratings

    $JAZZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

      First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomization First Phase 3 study to demonstrate statistically significant and clinically meaningful improvements in both progression-free and overall survival in ES-SCLC first-line maintenance Results presented at the ASCO 2025 Annual Meeting and simultaneously published in The Lancet Jazz to host investor webcast on Tuesday, June 10 to review Zepzelca data For U.S. media and investors only DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced positive re

      6/2/25 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025

      Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up, with a manageable safety profile Findings presented today at ASCO 2025 and concurrently published in The Lancet Oncology For U.S. media and investors only  DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced long-term data, including the first report of median overall survival (OS) from the Phase 2 trial evaluating Ziihera® (zanidatamab-hrii), a dual HER2-targeted bispecific antibody, in combination with chemotherapy for the investigational use in first-line HER2-positive (IHC 3+ or IHC

      6/2/25 12:35:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025

      Nineteen abstracts, including eleven late-breaking abstracts, underscore Jazz's leadership and extensive research in sleep medicine, and ongoing commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia For U.S. media and investors only DUBLIN, May 29, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nineteen abstracts, including eleven late-breaking abstracts will be presented at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies (APSS) being held June 8-11, 2025, in Seattle. Research to be presented at the meeting include dual late-breaking poster and oral presentations, which highlight the extensive Phas

      5/29/25 7:30:00 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Jazz Pharmaceuticals plc

      DEFA14A - Jazz Pharmaceuticals plc (0001232524) (Filer)

      6/6/25 4:09:11 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Jazz Pharmaceuticals plc

      DEF 14A - Jazz Pharmaceuticals plc (0001232524) (Filer)

      6/6/25 4:06:54 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Jazz Pharmaceuticals plc

      144 - Jazz Pharmaceuticals plc (0001232524) (Subject)

      6/2/25 5:03:17 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jazz Pharma upgraded by UBS with a new price target

      UBS upgraded Jazz Pharma from Neutral to Buy and set a new price target of $179.00 from $145.00 previously

      3/7/25 8:10:15 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharma downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Jazz Pharma from Overweight to Neutral

      2/26/25 1:51:25 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharma upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Jazz Pharma from Equal Weight to Overweight and set a new price target of $170.00 from $130.00 previously

      2/13/25 8:08:59 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mulligan Seamus bought $9,993,082 worth of Ordinary Shares (101,621 units at $98.34) (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      5/13/25 6:51:34 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson Philip L was granted 15,932 units of Ordinary Shares and bought $1,435,800 worth of Ordinary Shares (12,000 units at $119.65) (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      3/5/24 7:28:40 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • August 12, 2021 - FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment

      For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl

      8/12/21 4:25:43 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

      SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

      2/13/24 5:07:58 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

      SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

      9/11/23 1:33:44 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

      SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

      2/9/23 11:25:15 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman & CEO Cozadd Bruce C sold $108,950 worth of Ordinary Shares (1,000 units at $108.95), decreasing direct ownership by 0.23% to 437,973 units (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      6/4/25 4:50:28 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mulligan Seamus bought $9,993,082 worth of Ordinary Shares (101,621 units at $98.34) (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      5/13/25 6:51:34 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman & CEO Cozadd Bruce C sold $176,350 worth of Ordinary Shares (1,500 units at $117.57), decreasing direct ownership by 0.34% to 438,807 units (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      5/5/25 7:00:39 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Financials

    Live finance-specific insights

    See more

    $JAZZ
    Leadership Updates

    Live Leadership Updates

    See more
    • Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

      DUBLIN, April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2025 first quarter financial results and provide a business and financial update.   Audio webcast/conference call:U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are available here.Passcode: 5080203 Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at

      4/22/25 4:15:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Completes Acquisition of Chimerix

      - Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN, April 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chimerix") for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz. "Bringing Chimerix into Jazz adds a novel medicine to our oncology portfolio and advances our efforts to address unmet patient needs," said Bruce Cozadd, chairman and chief executive officer of Jazz. "Dordaviprone has the potential to become the first an

      4/21/25 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

      – Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –– Xywav® and Epidiolex® revenues grew 16% and 15% year-over-year, respectively, in 2024 –– Oncology revenues grew 9% year-over-year in 2024, surpassed $1.1 billion –– Ziihera® approved in 2L HER2+ (IHC3+) BTC; first sales achieved in December 2024 –– 2025 guidance reflects continued top- and bottom-line growth – DUBLIN, Feb. 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the full year and fourth quarter of 2024 and provided guidance for 2025. "2024 was another strong year as our proven team delivered significant top- and bottom-line growth along with record total r

      2/25/25 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Announces CEO Succession Plan

      Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025 DUBLIN, Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of the Company's next leader, expected by the end of 2025. The Board wil

      12/16/24 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting

      Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN, July 25, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the election of a new independent director, Laura Hamill, to its Board of Directors. Ms. Hamill, a 35-year veteran of the pharmaceutical industry brings broad executive leadership and global commercial operations expertise to the company's Board. Ms. Hamill's election follows the appointment of Patrick Kennedy earlier this year and reflects Jazz's continued focus on Board renewal. At the Annual General meeting held today, shareholders not only elected Ms. Hamill and Mr. Kennedy but also re-

      7/25/24 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer

      NodThera INC ("NodThera" or the "Company") NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership experience, including as President and COO of Jazz Pharmaceuticals and CEO of Sunesis PharmaceuticalsInterim CEO Alan Watt becomes President and CSO including leadership of R&D to further build out NodThera's pioneering work in CNS modulation of chronic inflammatory diseases BOSTON, MA, May 28, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the a

      5/28/24 7:00:00 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care